Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Erdem, Şen"'
Publikováno v:
Journal of Oncological Sciences, Vol 3, Iss 2, Pp 92-95 (2017)
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated. The most common adverse events report
Externí odkaz:
https://doaj.org/article/b8bebdaee9f94a4884c246843f7995d4
Autor:
Cihan, Erol, Abdullah, Sakin, Tuğba, Başoğlu, Ercan, Özden, Devrim, Çabuk, Mutlu, Doğan, Berna, Öksüzoğlu, Hasan Çağrı, Yıldırım, İrem, Öner, Melek Karakurt, Eryılmaz, Özgecan, Dülgar, Dinçer, Aydın, Neslihan, Doğan, Miraç, Özen, İlhan, Hacıbekiroğlu, Nuriye, Özdemir, Fatih, Gürler, Nail, Paksoy, Senem, Karabulut, Asude, Aksoy, Mutlu, Hızal, Seda, Kahraman, Erdem, Şen, Semra, Paydaş, Ebru, Çılbır, Feyza, Fırat, Nadiye, Akdeniz, Melike, Özçelik, Abdilkerim, Oyman, Naziyet Köse, Baytemür, Ramazan, Acar, Elvina, Almuradova, Bülent, Karabulut, Teoman, Şakalar, Hacı, Arak, Ezgi, Değerli, Sema, Türker, Özkan, Alan, Özlem, Er, Elif Şenocak, Taşçı, Nazan, Demir, Eyyüp, Çavdar, Serdar, Turhal, Didem Şener, Dede, Muhammed Bülent, Akıncı, Bülent, Yalçın, Fulden, Yumuk, Şuayib, Yalçın, Mehmet Ali Nahit, Şendur
Publikováno v:
Turkish journal of medical sciences. 52(4)
Perioperative FLOT regimen is a standard of care in locally advanced operable gastric and GEJ adenocarcinoma. We aimed to determine the efficacy, prognostic factors of perioperative FLOT chemotherapy in real-life gastric and GEJ tumors.The data of pa
Publikováno v:
Respiratory Case Reports. 8:26-30
Publikováno v:
International Journal of Gynecologic Cancer. 29:42-47
IntroductionStandard treatment for locally advanced cervical cancer (LACC) includes concomitant chemoradiotherapy (CRT) that typically controls localized disease. However, most patients develop distant metastasis, ultimately leading to death.Objectiv
Publikováno v:
Acta Oncologica Turcica. 51:87-90
Publikováno v:
Acta Oncologica Turcica. 51:110-117
Publikováno v:
Journal of Oncological Sciences, Vol 3, Iss 2, Pp 92-95 (2017)
Imatinib mesylate is a potent inhibitor of the BCR-Abl kinases, c-Kit, PDGFR, and fms. Imatinib used for treatment of chronic myeloid leukemia and gastrointestinal stromal tumor. Imatinib has been well tolerated. The most common adverse events report
Publikováno v:
Turkiye Klinikleri Journal of Case Reports. 25:55-58
Publikováno v:
Archives of Clinical and Medical Case Reports. :35-41
Vaginal malignant melanoma is a rare form of mucosal melanoma, and accounts for only
Publikováno v:
Acta Oncologica Turcica. 51:256-258